VK-II-36
CAS No. 955371-66-1
VK-II-36( —— )
Catalog No. M25009 CAS No. 955371-66-1
VK-II-36, a carvedilol analog, suppresses sarcoplasmic reticulum (SR) Ca(2+) release but does not block the β-receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 222 | In Stock |
|
10MG | 357 | In Stock |
|
25MG | 597 | In Stock |
|
50MG | 851 | In Stock |
|
100MG | 1152 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVK-II-36
-
NoteResearch use only, not for human use.
-
Brief DescriptionVK-II-36, a carvedilol analog, suppresses sarcoplasmic reticulum (SR) Ca(2+) release but does not block the β-receptor.
-
DescriptionVK-II-36, a carvedilol analog, suppresses sarcoplasmic reticulum (SR) Ca(2+) release but does not block the β-receptor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number955371-66-1
-
Formula Weight446.49
-
Molecular FormulaC26H26N2O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCOC1=CC=CC=C1OCCN2CC(OCC2=O)COC3=CC=CC4=C3C5=CC=CC=C5N4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chen S R W , Joung B , Shinohara T , et al. Carvedilol analog modulates both basal and stimulated sinoatrial node automaticity.[J]. Heart and vessels: An international journal, 2014.
molnova catalog
related products
-
Glycerol Tridecanoat...
Glycerol Tridecanoate is also known as triacylglycerols or triacylglycerides. The triglycerides are rebuilt in the blood from their fragments and become constituents of lipoproteins which deliver the fatty acids to and from fat cells among other functions. Various tissues can release free fatty acids and take them up as a source of energy.
-
Centhaquine
Centhaquine is an adrenergic receptor potentially for the treatment of postoperative pain and for the resuscitation of hypovolemic shock.
-
PCNA-I1
PCNA-I1 is an inhibitor targeting PCNA chromatin association in prostate cancer.